Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study

Lancet

Volumn 363, Issue 9423, 2004, Pages 1751-1756

  Mamdani, Muhammad ^a,b,c   Juurlink, David N ^a,c,d   Lee, Douglas S ^a,c   Rochon, Paula A ^a,c,f   Kopp, Alex ^a,c   Naglie, Gary ^a,c,e   Austin, Peter C ^a,c   Laupacis, Andreas ^a,c,d   Stukel, Therese A ^a,c  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

^f BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SELECTIVITY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 2542570187     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16299-5     Document Type: Article

References (27)

1. IMS Health Canada. New arthritis medication achieves fastest adoption ever recorded in Canada. http://www.imshealthcanada.com/htmen/4_2_1_15.htm (accessed April 16, 2004).
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study - a randomized controlled trial. JAMA. 284:2000;1247-1255
3. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528
4. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 325:2002;624-627
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959
6. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 360:2002;1071-1073
7. Frishman WH. Effects of non-steroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002; 89 (suppl): 18D-25D.
8. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognized public health problem. Arch Intern Med. 160:2000;777-784
9. Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BHC, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 158:1998;1108-1112
10. Feenstra J, Heerdink ER, Grobbee DE, Stricker BHC. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam study. Arch Intern Med. 162:2002;265-270
11. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 66:1999;76-84
12. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 289:1999;735-741
13. FDA Arthritis Advisory Committee Meeting, February, 2001. Celecoxib. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf (accessed May 2, 2004).
14. FDA Arthritis Advisory Committee Meeting, February, 2001. Rofecoxib. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf (accessed May 2, 2004).
15. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 287:2002;64-71
16. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 72:2002;50-61
17. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients >65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 90:2002;959-963
18. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 8:2001;85-95
19. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 10:2003;67-71
20. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation. 108:2003;184-191
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 154:2001;854-864
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 40:1987;373-383
23. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 14:2003;240-246
24. Feldman DE, Thivierge C, Guerard L, et al. Changing trends in mortality and admissions to hospital for elderly patients with congestive heart failure in Montreal. Can Med Assoc J. 165:2001;1033-1036
25. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 163:2003;481-486
26. Vioxx ® (Rofecoxib). US Product information, 2003. http://www.merckfrosst.ca/e/products/monographs/VIOXX_867-a_10_03-PI-E.pdf (accessed May 2, 2004).
27. Townend JN, Doran J, Lote CJ, Davies MK. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J. 73:1995;434-441